Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Apr 03, 2014 2:00pm
161 Views
Post# 22407071

RE:Investment Conferences

RE:Investment ConferencesSanfran, it is always so helpful to receive your perspectives from the point of view of your long term perspective of the company, it's people and how they have approached their business.

I came to the conclusion a week or 2 ago that this company and it's partners are a remarkably talented group of people and surely understand their science as well as any experts could.

The continued support of Eastern and NGN is a very strong vote of confidence.

My intial perception of the conference attendance was that it is good because it is getting in front of investors. But then I thought WHY if they already are nearing the completion of a deal. But, it's never good to stop until the i's are dotted and t's crossed.

My area of expertise is brand positioning, communications strategy development and market research, hence I've been harping on the gap in expertise that I see there. It's is often very difficult to shift a paradigm and culture when looking in from the outside but I hope someone gets the message because there is value in it. Enough said on that front.

I feel hopeful and I'm holding my position.

Cheers
Toinv
Bullboard Posts